Fund moves
4.8%Stake
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
HSIC · NASDAQ · Health Care Distributors
Henry Schein (HSIC) · oqro.io/stocks/HSIC · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Henry Schein was filed in the last 90 days. The latest on record was on May 12, 2026.
Since 2006, Henry Schein insiders reported 21 open-market purchases and 786 sales on Forms 4 and 5, with purchases in 12 different years, most recently 2026.
No open-market sale by an insider of Henry Schein (HSIC) was filed with the SEC in the last 90 days.
No trade in Henry Schein (HSIC) was disclosed by a member of Congress in the last 12 months.
Henry Schein's next results are expected on Feb 22, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$85.69+2.75 (+3.32%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+20.4% (+$14.49) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $71.20 on Nov 18, 2025 to $85.69 on Nov 18, 2026 (+20.4%). Disclosed in this range: 11 insider trades, 0 pre-arranged insider sales, 0 Congress trades, and 23 13F position changes for 3 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Distributors company based in Melville, New York.
Last 12 months
+20.4%
Market value
$9.47B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 9.36M shares sold short (8.5% of shares outstanding), +4.0% vs the previous count, 8.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$3.47B
+4.0% vs the same quarter a year earlier
Free cash flow, last 12 months
$559M
This quarter $131M, a year earlier $141M
Net debt
$2.2B
Debt $2.38B, cash $184M, at Sep 26, 2026
Net income, last 12 months
$421M
Operating profit covers interest 4.3x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 3, 2026.
Revenue, fiscal 2025
$13.2B
+4.0% vs the year before
Net income, fiscal 2025
$398M
As reported in the annual filing
Shares outstanding
111M
As of Oct 26, 2026
In fiscal 2025 the company spent $850M buying back its own shares. Cash actually paid, from its cash-flow statement.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Federal contracts
This award provides ICE enforcement and removal operations detention facilities with dental delivery units used to provide dental services.
The Department of Homeland Security has committed $584K to Henry Schein so far. It runs until Sep 29, 2027.
Federal contracts
The purpose of installation of cabinet workstation within the sterile compound room at the pueblo pintado clinic
The Department of Health and Human Services has committed $63K to Henry Schein so far. It runs until Aug 25, 2027.
Federal contracts
Specialized dental preventive maintenance & repair service for all dental equipment
The Department of Health and Human Services has committed $60K to Henry Schein so far. The contract could grow to $150K. It runs until Jan 5, 2028.
Fund moves
16 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Top officer leaving
“Lowery commences employment with the Company, and then following his retirement as Chief Executive Officer Mr.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Henry Schein reported 21 open-market purchases and 786 sales since 2006; purchases in 12 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $692K1×1 trade | $8.58M10×10 trades |
| 2025 | $671K1×1 trade | $672K3×3 trades |
| 2024 | — | $4.23M9×9 trades |
| 2023 | — | $13.1M15×15 trades |
| 2022 | $86K1×1 trade | $17M20×20 trades |
| 2021 | $114K2×2 trades | $8.31M11×11 trades |
| 2020 | — | $8.05M13×13 trades |
| 2019 | $121K1×1 trade | $12.6M19×19 trades |
| 2018 | — | $10.3M14×14 trades |
| 2017 | $86K1×1 trade | $20.4M26×26 trades |
| 2016 | $193K3×3 trades | $34M37×37 trades |
| 2015 | — | $34.2M51×51 trades |
| 2014 | $67K2×2 trades | $55.3M63×63 trades |
| 2013 | — | $61.6M53×53 trades |
| 2012 | — | $70.1M52×52 trades |
| 2011 | $50K6×6 trades | $20.5M27×27 trades |
| 2010 | $60K1×1 trade | $26M25×25 trades |
| 2009 | $31K1×1 trade | $3.27M7×7 trades |
| 2008 | $31K1×1 trade | $12.3M57×57 trades |
| 2007 | — | $24.4M122×122 trades |
| 2006 | — | $13.6M152×152 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the public record for Henry Schein over the 12 months to Nov 18, 2026: 15 FDA records.
1 certified in FY2026 Q3, vs 1 a year earlier. 1 position in total, median offered wage $150K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
People read Henry Schein's Wikipedia article about 54 times a day over the last week, close to the 56 on a usual day of the three months before.
May 14, 2026Busiest day: 160 views on Jun 17, 2026Nov 18, 2026
Views of the article Henry Schein, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
Latest annual report filed Feb 24, 2026, compared with the one filed Feb 25, 2025. Read the filing
All 28 risk factor headings match the year before, give or take wording.
For a discussion of Legal Proceedings, see Note 17 – Commitments and Contingencies: of the Notes to the Consolidated Financial Statements included under Item 8.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 24, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
0 approvals or clearances and 15 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
KKR Group Partnership L.P.
13D · may seek influence · Up from 15.2% · 18.9M shares · filed Mar 10, 2026
FMR LLC
13G · passive · Crossed 5% · 7.55M shares · filed Aug 6, 2026
Vanguard Capital Management
13G · passive · Crossed 5% · 7.3M shares · filed Apr 30, 2026
Recent moves
Artisan Partners Asset Management Inc. fell below 5% (4.8%) · Schedule 13G, 2026
FMR LLC went above 5%, with 6.6% · Schedule 13G, 2026
Vanguard Capital Management went above 5%, with 6.36% · Schedule 13G, 2026
The Vanguard Group fell below 5% (0%) · Schedule 13G, 2026
KKR Group Partnership L.P. raised its stake to 16.4% from 15.2% · Schedule 13D, 2026
KKR Group Partnership L.P. raised its stake to 15.2% from 14.9% · Schedule 13D, 2025
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Against the S&P 500 over the year
Since Nov 17, 2025, HSIC is up 20.3% and the index fund is up 9.7%: 11 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much HSIC moves
Beta 0.6 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Last results
Nov 3, 2026
Within the 30 days after it, until Dec 3, 2026
Next results, expected
Feb 22, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
90%
9 of 10 insider purchases since 2016 came within 30 days after a results announcement
From Henry Schein's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Henry Schein's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Short sale volume: 38.4% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 58.1%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 16K shares (about $1.33M) were not delivered on time for settlement on Oct 7, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
Off-exchange trading: 44.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (33.9% on ATS, 10.4% with other brokers), close to its 26-week average of 43.7%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: UBS ATS (13.4%), INTELLIGENT CROSS LLC (11.0%), SIGMA X2 (10.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
Records